Skip to main content
Top

Open Access 06-07-2024 | Bariatric Surgery | Review Article

Pharmacotherapy as an Augmentation to Bariatric Surgery for Obesity

Authors: Luděk Horváth, Miloš Mráz, Edward B. Jude, Martin Haluzík

Published in: Drugs

Login to get access

Abstract

A global obesity pandemic is one of the most significant health threats worldwide owing to its close association with numerous comorbidities such as type 2 diabetes mellitus, arterial hypertension, dyslipidemia, heart failure, cancer and many others. Obesity and its comorbidities lead to a higher rate of cardiovascular complications, heart failure and increased cardiovascular and overall mortality. Bariatric surgery is at present the most potent therapy for obesity, inducing a significant weight loss in the majority of patients. In the long-term, a substantial proportion of patients after bariatric surgery experience a gradual weight regain that may, in some, reach up to a presurgical body weight. As a result, anti-obesity pharmacotherapy may be needed in some patients after bariatric surgery to prevent the weight regain or to further potentiate weight loss. This article provides an overview of the use of anti-obesity medications as an augmentation to bariatric surgery for obesity. Despite relatively limited published data, it can be concluded that anti-obesity medication can serve as an effective adjunct therapy to bariatric surgery to help boost post-bariatric weight loss or prevent weight regain.
Literature
1.
go back to reference Committee on Accelerating Progress in Obesity P, Food, Nutrition B, et al. In: Glickman D, Parker L, Sim LJ, Del Valle Cook H, Miller EA (eds). Accelerating progress in obesity prevention: solving the weight of the nation. Washington (DC): National Academies Press (US). Copyright 2012 by the National Academy of Sciences. All rights reserved.; 2012. Committee on Accelerating Progress in Obesity P, Food, Nutrition B, et al. In: Glickman D, Parker L, Sim LJ, Del Valle Cook H, Miller EA (eds). Accelerating progress in obesity prevention: solving the weight of the nation. Washington (DC): National Academies Press (US). Copyright 2012 by the National Academy of Sciences. All rights reserved.; 2012.
2.
go back to reference Pierce SL, Kompaniyets L, Freedman DS, et al. Children’s rates of BMI change during pre-pandemic and two COVID-19 pandemic periods, IQVIA Ambulatory Electronic Medical Record, January 2018 Through November 2021. Obesity. 2023;31(3):693–8.PubMedCrossRef Pierce SL, Kompaniyets L, Freedman DS, et al. Children’s rates of BMI change during pre-pandemic and two COVID-19 pandemic periods, IQVIA Ambulatory Electronic Medical Record, January 2018 Through November 2021. Obesity. 2023;31(3):693–8.PubMedCrossRef
5.
go back to reference Shariq OA, McKenzie TJ. Obesity-related hypertension: a review of pathophysiology, management, and the role of metabolic surgery. Gland Surg. 2020;9(1):80–93.PubMedPubMedCentralCrossRef Shariq OA, McKenzie TJ. Obesity-related hypertension: a review of pathophysiology, management, and the role of metabolic surgery. Gland Surg. 2020;9(1):80–93.PubMedPubMedCentralCrossRef
6.
go back to reference Bays HE, Toth PP, Kris-Etherton PM, et al. Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association. J Clin Lipidol. 2013;7(4):304–83.PubMedCrossRef Bays HE, Toth PP, Kris-Etherton PM, et al. Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association. J Clin Lipidol. 2013;7(4):304–83.PubMedCrossRef
8.
go back to reference Leitner DR, Frühbeck G, Yumuk V, et al. Obesity and type 2 diabetes: two diseases with a need for combined treatment strategies—EASO can lead the way. Obes Facts. 2017;10(5):483–92.PubMedPubMedCentralCrossRef Leitner DR, Frühbeck G, Yumuk V, et al. Obesity and type 2 diabetes: two diseases with a need for combined treatment strategies—EASO can lead the way. Obes Facts. 2017;10(5):483–92.PubMedPubMedCentralCrossRef
9.
go back to reference Kiran HKP, Rohin KR, Arunashis S, et al. Obesity as a risk factor for cardiac arrhythmias. BMJ Med. 2022;1(1):e000308.CrossRef Kiran HKP, Rohin KR, Arunashis S, et al. Obesity as a risk factor for cardiac arrhythmias. BMJ Med. 2022;1(1):e000308.CrossRef
10.
go back to reference Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51(2):679–89.PubMedCrossRef Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51(2):679–89.PubMedCrossRef
11.
go back to reference Romero-Corral A, Caples SM, Lopez-Jimenez F, et al. Interactions between obesity and obstructive sleep apnea: implications for treatment. Chest. 2010;137(3):711–9.PubMedPubMedCentralCrossRef Romero-Corral A, Caples SM, Lopez-Jimenez F, et al. Interactions between obesity and obstructive sleep apnea: implications for treatment. Chest. 2010;137(3):711–9.PubMedPubMedCentralCrossRef
12.
go back to reference Pati S, Irfan W, Jameel A, et al. Obesity and cancer: a current overview of epidemiology, pathogenesis, outcomes, and management. Cancers (Basel). 2023;15(2):485.PubMedPubMedCentralCrossRef Pati S, Irfan W, Jameel A, et al. Obesity and cancer: a current overview of epidemiology, pathogenesis, outcomes, and management. Cancers (Basel). 2023;15(2):485.PubMedPubMedCentralCrossRef
13.
go back to reference Singh-Manoux A, Dugravot A, Shipley M, et al. Obesity trajectories and risk of dementia: 28 years of follow-up in the Whitehall II Study. Alzheimers Dement. 2018;14(2):178–86.PubMedCrossRef Singh-Manoux A, Dugravot A, Shipley M, et al. Obesity trajectories and risk of dementia: 28 years of follow-up in the Whitehall II Study. Alzheimers Dement. 2018;14(2):178–86.PubMedCrossRef
14.
go back to reference Obalum DC, Fiberesima F, Eyesan SU, et al. A review of obesity and orthopaedic surgery: the critical issues. Niger Postgrad Med J. 2012;19(3):175–80.PubMedCrossRef Obalum DC, Fiberesima F, Eyesan SU, et al. A review of obesity and orthopaedic surgery: the critical issues. Niger Postgrad Med J. 2012;19(3):175–80.PubMedCrossRef
15.
go back to reference Gkastaris K, Goulis DG, Potoupnis M, et al. Obesity, osteoporosis and bone metabolism. J Musculoskelet Neuronal Interact. 2020;20(3):372–81.PubMedPubMedCentral Gkastaris K, Goulis DG, Potoupnis M, et al. Obesity, osteoporosis and bone metabolism. J Musculoskelet Neuronal Interact. 2020;20(3):372–81.PubMedPubMedCentral
17.
go back to reference Kushner RF. Weight loss strategies for treatment of obesity. Prog Cardiovasc Dis. 2014;56(4):465–72.PubMedCrossRef Kushner RF. Weight loss strategies for treatment of obesity. Prog Cardiovasc Dis. 2014;56(4):465–72.PubMedCrossRef
18.
20.
go back to reference Koliaki C, Liatis S, le Roux CW, et al. The role of bariatric surgery to treat diabetes: current challenges and perspectives. BMC Endocr Disord. 2017;17(1):50.PubMedPubMedCentralCrossRef Koliaki C, Liatis S, le Roux CW, et al. The role of bariatric surgery to treat diabetes: current challenges and perspectives. BMC Endocr Disord. 2017;17(1):50.PubMedPubMedCentralCrossRef
21.
go back to reference Madsen LR, Baggesen LM, Richelsen B, et al. Effect of Roux-en-Y gastric bypass surgery on diabetes remission and complications in individuals with type 2 diabetes: a Danish population-based matched cohort study. Diabetologia. 2019;62(4):611–20.PubMedCrossRef Madsen LR, Baggesen LM, Richelsen B, et al. Effect of Roux-en-Y gastric bypass surgery on diabetes remission and complications in individuals with type 2 diabetes: a Danish population-based matched cohort study. Diabetologia. 2019;62(4):611–20.PubMedCrossRef
22.
go back to reference Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366(17):1577–85.PubMedCrossRef Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366(17):1577–85.PubMedCrossRef
23.
go back to reference Cummings DE, Arterburn DE, Westbrook EO, et al. Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial. Diabetologia. 2016;59(5):945–53.PubMedPubMedCentralCrossRef Cummings DE, Arterburn DE, Westbrook EO, et al. Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial. Diabetologia. 2016;59(5):945–53.PubMedPubMedCentralCrossRef
24.
go back to reference Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): indications for metabolic and bariatric surgery. Surg Obes Relat Dis. 2022;18(12):1345–56.PubMedCrossRef Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): indications for metabolic and bariatric surgery. Surg Obes Relat Dis. 2022;18(12):1345–56.PubMedCrossRef
26.
go back to reference Billeter AT, Fischer L, Wekerle AL, et al. Malabsorption as a therapeutic approach in bariatric surgery. Viszeralmedizin. 2014;30(3):198–204.PubMedPubMedCentral Billeter AT, Fischer L, Wekerle AL, et al. Malabsorption as a therapeutic approach in bariatric surgery. Viszeralmedizin. 2014;30(3):198–204.PubMedPubMedCentral
28.
go back to reference Bohdjalian A, Langer FB, Shakeri-Leidenmühler S, et al. Sleeve gastrectomy as sole and definitive bariatric procedure: 5-year results for weight loss and ghrelin. Obes Surg. 2010;20(5):535–40.PubMedCrossRef Bohdjalian A, Langer FB, Shakeri-Leidenmühler S, et al. Sleeve gastrectomy as sole and definitive bariatric procedure: 5-year results for weight loss and ghrelin. Obes Surg. 2010;20(5):535–40.PubMedCrossRef
29.
go back to reference Langer FB, Bohdjalian A, Shakeri-Leidenmühler S, et al. Conversion from sleeve gastrectomy to Roux-en-Y gastric bypass–indications and outcome. Obes Surg. 2010;20(7):835–40.PubMedCrossRef Langer FB, Bohdjalian A, Shakeri-Leidenmühler S, et al. Conversion from sleeve gastrectomy to Roux-en-Y gastric bypass–indications and outcome. Obes Surg. 2010;20(7):835–40.PubMedCrossRef
30.
go back to reference Cooper TC, Simmons EB, Webb K, et al. Trends in weight regain following Roux-en-Y Gastric Bypass (RYGB) bariatric surgery. Obes Surg. 2015;25(8):1474–81.PubMedCrossRef Cooper TC, Simmons EB, Webb K, et al. Trends in weight regain following Roux-en-Y Gastric Bypass (RYGB) bariatric surgery. Obes Surg. 2015;25(8):1474–81.PubMedCrossRef
31.
go back to reference King WC, Hinerman AS, Belle SH, et al. Comparison of the performance of common measures of weight regain after bariatric surgery for association with clinical outcomes. JAMA. 2018;320(15):1560–9.PubMedPubMedCentralCrossRef King WC, Hinerman AS, Belle SH, et al. Comparison of the performance of common measures of weight regain after bariatric surgery for association with clinical outcomes. JAMA. 2018;320(15):1560–9.PubMedPubMedCentralCrossRef
32.
go back to reference Flint RS, Coulter G, Roberts R. The pattern of adjustments after laparoscopic adjustable gastric band. Obes Surg. 2015;25(11):2061–5.PubMedCrossRef Flint RS, Coulter G, Roberts R. The pattern of adjustments after laparoscopic adjustable gastric band. Obes Surg. 2015;25(11):2061–5.PubMedCrossRef
33.
go back to reference Brethauer SA, Kothari S, Sudan R, et al. Systematic review on reoperative bariatric surgery: American Society for Metabolic and Bariatric Surgery Revision Task Force. Surg Obes Relat Dis. 2014;10(5):952–72.PubMedCrossRef Brethauer SA, Kothari S, Sudan R, et al. Systematic review on reoperative bariatric surgery: American Society for Metabolic and Bariatric Surgery Revision Task Force. Surg Obes Relat Dis. 2014;10(5):952–72.PubMedCrossRef
34.
go back to reference Dang JT, Vaughan T, Mocanu V, et al. Conversion of sleeve gastrectomy to Roux-en-Y gastric bypass: indications, prevalence, and safety. Obes Surg. 2023;33(5):1486–93.PubMedPubMedCentralCrossRef Dang JT, Vaughan T, Mocanu V, et al. Conversion of sleeve gastrectomy to Roux-en-Y gastric bypass: indications, prevalence, and safety. Obes Surg. 2023;33(5):1486–93.PubMedPubMedCentralCrossRef
35.
go back to reference Alalwan AA, Friedman J, Park H, et al. US national trends in bariatric surgery: a decade of study. Surgery. 2021;170(1):13–7.PubMedCrossRef Alalwan AA, Friedman J, Park H, et al. US national trends in bariatric surgery: a decade of study. Surgery. 2021;170(1):13–7.PubMedCrossRef
36.
go back to reference Seeras K, Sankararaman S, Lopez PP. Sleeve gastrectomy. StatPearls. Treasure Island (FL): StatPearls Publishing. Copyright © 2023, StatPearls Publishing LLC.; 2023. Seeras K, Sankararaman S, Lopez PP. Sleeve gastrectomy. StatPearls. Treasure Island (FL): StatPearls Publishing. Copyright © 2023, StatPearls Publishing LLC.; 2023.
37.
go back to reference Rosen DJ, Dakin GF, Pomp A. Sleeve gastrectomy. Minerva Chir. 2009;64(3):285–95.PubMed Rosen DJ, Dakin GF, Pomp A. Sleeve gastrectomy. Minerva Chir. 2009;64(3):285–95.PubMed
39.
go back to reference Landreneau JP, Strong AT, Rodriguez JH, et al. Conversion of sleeve gastrectomy to Roux-en-Y gastric bypass. Obes Surg. 2018;28(12):3843–50.PubMedCrossRef Landreneau JP, Strong AT, Rodriguez JH, et al. Conversion of sleeve gastrectomy to Roux-en-Y gastric bypass. Obes Surg. 2018;28(12):3843–50.PubMedCrossRef
40.
go back to reference Scott WR, Batterham RL. Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: understanding weight loss and improvements in type 2 diabetes after bariatric surgery. Am J Physiol Regul Integr Comp Physiol. 2011;301(1):R15–27.PubMedCrossRef Scott WR, Batterham RL. Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: understanding weight loss and improvements in type 2 diabetes after bariatric surgery. Am J Physiol Regul Integr Comp Physiol. 2011;301(1):R15–27.PubMedCrossRef
41.
go back to reference Arterburn DE, Johnson E, Coleman KJ, et al. Weight outcomes of sleeve gastrectomy and gastric bypass compared to nonsurgical treatment. Ann Surg. 2021;274(6):e1269–76.PubMedCrossRef Arterburn DE, Johnson E, Coleman KJ, et al. Weight outcomes of sleeve gastrectomy and gastric bypass compared to nonsurgical treatment. Ann Surg. 2021;274(6):e1269–76.PubMedCrossRef
42.
go back to reference Wu W, Widjaja J, Lu S, et al. Comparison of the outcomes of single anastomosis duodeno-ileostomy with sleeve gastrectomy (SADI-S), single anastomosis sleeve ileal (SASI) bypass with sleeve gastrectomy, and sleeve gastrectomy using a rodent model with diabetes. Obes Surg. 2022;32(4):1209–15.PubMedCrossRef Wu W, Widjaja J, Lu S, et al. Comparison of the outcomes of single anastomosis duodeno-ileostomy with sleeve gastrectomy (SADI-S), single anastomosis sleeve ileal (SASI) bypass with sleeve gastrectomy, and sleeve gastrectomy using a rodent model with diabetes. Obes Surg. 2022;32(4):1209–15.PubMedCrossRef
44.
go back to reference Kamocka A, Chidambaram S, Erridge S, et al. Length of biliopancreatic limb in Roux-en-Y gastric bypass and its impact on post-operative outcomes in metabolic and obesity surgery—systematic review and meta-analysis. Int J Obes. 2022;46(11):1983–91.CrossRef Kamocka A, Chidambaram S, Erridge S, et al. Length of biliopancreatic limb in Roux-en-Y gastric bypass and its impact on post-operative outcomes in metabolic and obesity surgery—systematic review and meta-analysis. Int J Obes. 2022;46(11):1983–91.CrossRef
45.
go back to reference Nergaard BJ, Leifsson BG, Hedenbro J, et al. Gastric bypass with long alimentary limb or long pancreato-biliary limb–long-term results on weight loss, resolution of co-morbidities and metabolic parameters. Obes Surg. 2014;24(10):1595–602.PubMedPubMedCentralCrossRef Nergaard BJ, Leifsson BG, Hedenbro J, et al. Gastric bypass with long alimentary limb or long pancreato-biliary limb–long-term results on weight loss, resolution of co-morbidities and metabolic parameters. Obes Surg. 2014;24(10):1595–602.PubMedPubMedCentralCrossRef
46.
go back to reference Golzarand M, Toolabi K, Farid R. The bariatric surgery and weight losing: a meta-analysis in the long- and very long-term effects of laparoscopic adjustable gastric banding, laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy on weight loss in adults. Surg Endosc. 2017;31(11):4331–45.PubMedCrossRef Golzarand M, Toolabi K, Farid R. The bariatric surgery and weight losing: a meta-analysis in the long- and very long-term effects of laparoscopic adjustable gastric banding, laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy on weight loss in adults. Surg Endosc. 2017;31(11):4331–45.PubMedCrossRef
47.
go back to reference Robert L, Alec B, Dirk CJ, et al. Early and late complications of bariatric operation. Trauma Surg Acute Care Open. 2018;3(1): e000219.CrossRef Robert L, Alec B, Dirk CJ, et al. Early and late complications of bariatric operation. Trauma Surg Acute Care Open. 2018;3(1): e000219.CrossRef
48.
go back to reference Chahal-Kummen M, Salte OBK, Hewitt S, et al. Health benefits and risks during 10 years after Roux-en-Y gastric bypass. Surg Endosc. 2020;34(12):5368–76.PubMedPubMedCentralCrossRef Chahal-Kummen M, Salte OBK, Hewitt S, et al. Health benefits and risks during 10 years after Roux-en-Y gastric bypass. Surg Endosc. 2020;34(12):5368–76.PubMedPubMedCentralCrossRef
49.
go back to reference Mahdy T, Al Wahedi A, Schou C. Efficacy of single anastomosis sleeve ileal (SASI) bypass for type-2 diabetic morbid obese patients: gastric bipartition, a novel metabolic surgery procedure: a retrospective cohort study. Int J Surg. 2016;34:28–34.PubMedCrossRef Mahdy T, Al Wahedi A, Schou C. Efficacy of single anastomosis sleeve ileal (SASI) bypass for type-2 diabetic morbid obese patients: gastric bipartition, a novel metabolic surgery procedure: a retrospective cohort study. Int J Surg. 2016;34:28–34.PubMedCrossRef
50.
go back to reference Tarnowski W, Barski K, Jaworski P, et al. Single anastomosis sleeve ileal bypass (SASI): a single-center initial report. Wideochir Inne Tech Maloinwazyjne. 2022;17(2):365–71.PubMedPubMedCentral Tarnowski W, Barski K, Jaworski P, et al. Single anastomosis sleeve ileal bypass (SASI): a single-center initial report. Wideochir Inne Tech Maloinwazyjne. 2022;17(2):365–71.PubMedPubMedCentral
52.
go back to reference Emile SH, Madyan A, Mahdy T, et al. Single anastomosis sleeve ileal (SASI) bypass versus sleeve gastrectomy: a case-matched multicenter study. Surg Endosc. 2021;35(2):652–60.PubMedCrossRef Emile SH, Madyan A, Mahdy T, et al. Single anastomosis sleeve ileal (SASI) bypass versus sleeve gastrectomy: a case-matched multicenter study. Surg Endosc. 2021;35(2):652–60.PubMedCrossRef
53.
go back to reference Aghajani E, Schou C, Gislason H, et al. Mid-term outcomes after single anastomosis sleeve ileal (SASI) bypass in treatment of morbid obesity. Surg Endosc. 2023;37(8):6220–7.PubMedPubMedCentralCrossRef Aghajani E, Schou C, Gislason H, et al. Mid-term outcomes after single anastomosis sleeve ileal (SASI) bypass in treatment of morbid obesity. Surg Endosc. 2023;37(8):6220–7.PubMedPubMedCentralCrossRef
54.
go back to reference Sánchez-Pernaute A, Rubio MÁ, Pérez Aguirre E, et al. Single-anastomosis duodenoileal bypass with sleeve gastrectomy: metabolic improvement and weight loss in first 100 patients. Surg Obes Relat Dis. 2013;9(5):731–5.PubMedCrossRef Sánchez-Pernaute A, Rubio MÁ, Pérez Aguirre E, et al. Single-anastomosis duodenoileal bypass with sleeve gastrectomy: metabolic improvement and weight loss in first 100 patients. Surg Obes Relat Dis. 2013;9(5):731–5.PubMedCrossRef
55.
go back to reference Shoar S, Poliakin L, Rubenstein R, et al. Single anastomosis duodeno-ileal switch (SADIS): a systematic review of efficacy and safety. Obes Surg. 2018;28(1):104–13.PubMedCrossRef Shoar S, Poliakin L, Rubenstein R, et al. Single anastomosis duodeno-ileal switch (SADIS): a systematic review of efficacy and safety. Obes Surg. 2018;28(1):104–13.PubMedCrossRef
56.
go back to reference Sánchez-Pernaute A, Herrera MÁR, Ferré NP, et al. Long-term results of single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S). Obes Surg. 2022;32(3):682–9.PubMedPubMedCentralCrossRef Sánchez-Pernaute A, Herrera MÁR, Ferré NP, et al. Long-term results of single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S). Obes Surg. 2022;32(3):682–9.PubMedPubMedCentralCrossRef
57.
go back to reference Andalib A, Bouchard P, Alamri H, et al. Single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S): short-term outcomes from a prospective cohort study. Surg Obes Relat Dis. 2021;17(2):414–24.PubMedCrossRef Andalib A, Bouchard P, Alamri H, et al. Single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S): short-term outcomes from a prospective cohort study. Surg Obes Relat Dis. 2021;17(2):414–24.PubMedCrossRef
58.
go back to reference Mahdy T, Gado W. Revisional surgery: sleeve to single anastomosis sleeve ileal (SASI) bypass. 2021. p. 579–88. Mahdy T, Gado W. Revisional surgery: sleeve to single anastomosis sleeve ileal (SASI) bypass. 2021. p. 579–88.
59.
go back to reference Dijkhorst PJ, Boerboom AB, Janssen IMC, et al. Failed sleeve gastrectomy: single anastomosis duodenoileal bypass or Roux-en-Y gastric bypass? A Multicenter Cohort Study. Obes Surg. 2018;28(12):3834–42.PubMedPubMedCentralCrossRef Dijkhorst PJ, Boerboom AB, Janssen IMC, et al. Failed sleeve gastrectomy: single anastomosis duodenoileal bypass or Roux-en-Y gastric bypass? A Multicenter Cohort Study. Obes Surg. 2018;28(12):3834–42.PubMedPubMedCentralCrossRef
60.
go back to reference Himpens J, Cadière GB, Bazi M, et al. Long-term outcomes of laparoscopic adjustable gastric banding. Arch Surg. 2011;146(7):802–7.PubMedCrossRef Himpens J, Cadière GB, Bazi M, et al. Long-term outcomes of laparoscopic adjustable gastric banding. Arch Surg. 2011;146(7):802–7.PubMedCrossRef
62.
go back to reference Himpens J, Dapri G, Cadière GB. A prospective randomized study between laparoscopic gastric banding and laparoscopic isolated sleeve gastrectomy: results after 1 and 3 years. Obes Surg. 2006;16(11):1450–6.PubMedCrossRef Himpens J, Dapri G, Cadière GB. A prospective randomized study between laparoscopic gastric banding and laparoscopic isolated sleeve gastrectomy: results after 1 and 3 years. Obes Surg. 2006;16(11):1450–6.PubMedCrossRef
64.
go back to reference Paccosi S, Cresci B, Pala L, et al. Obesity therapy: how and why? Curr Med Chem. 2020;27(2):174–86.PubMedCrossRef Paccosi S, Cresci B, Pala L, et al. Obesity therapy: how and why? Curr Med Chem. 2020;27(2):174–86.PubMedCrossRef
65.
go back to reference Walter CP, Bleske BE, Dorsch MP. Pharmacotherapy for weight loss: the cardiovascular effects of the old and new agents. J Clin Pharm Ther. 2014;39(5):475–84.PubMedCrossRef Walter CP, Bleske BE, Dorsch MP. Pharmacotherapy for weight loss: the cardiovascular effects of the old and new agents. J Clin Pharm Ther. 2014;39(5):475–84.PubMedCrossRef
66.
go back to reference Müller TD, Blüher M, Tschöp MH, et al. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201–23.PubMedCrossRef Müller TD, Blüher M, Tschöp MH, et al. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201–23.PubMedCrossRef
67.
go back to reference Richard D, Ferland J, Lalonde J, et al. Influence of topiramate in the regulation of energy balance. Nutrition. 2000;16(10):961–6.PubMedCrossRef Richard D, Ferland J, Lalonde J, et al. Influence of topiramate in the regulation of energy balance. Nutrition. 2000;16(10):961–6.PubMedCrossRef
68.
go back to reference Picard F, Deshaies Y, Lalonde J, et al. Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obes Res. 2000;8(9):656–63.PubMedCrossRef Picard F, Deshaies Y, Lalonde J, et al. Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obes Res. 2000;8(9):656–63.PubMedCrossRef
69.
go back to reference Lonneman DJ Jr, Rey JA, McKee BD. Phentermine/topiramate extended-release capsules (qsymia) for weight loss. P t. 2013;38(8):446–52.PubMedPubMedCentral Lonneman DJ Jr, Rey JA, McKee BD. Phentermine/topiramate extended-release capsules (qsymia) for weight loss. P t. 2013;38(8):446–52.PubMedPubMedCentral
70.
go back to reference VIVUS I. VI-0521 (Qnexa®) advisory committee briefing document. Endocrinologic and Metabolic Drugs Advisory Committee MeetingEaMDA; 2012. VIVUS I. VI-0521 (Qnexa®) advisory committee briefing document. Endocrinologic and Metabolic Drugs Advisory Committee MeetingEaMDA; 2012.
73.
go back to reference Lei XG, Ruan JQ, Lai C, et al. Efficacy and safety of phentermine/topiramate in adults with overweight or obesity: a systematic review and meta-analysis. Obesity (Silver Spring). 2021;29(6):985–94.PubMedCrossRef Lei XG, Ruan JQ, Lai C, et al. Efficacy and safety of phentermine/topiramate in adults with overweight or obesity: a systematic review and meta-analysis. Obesity (Silver Spring). 2021;29(6):985–94.PubMedCrossRef
74.
go back to reference Lei X-G, Ruan J-Q, Lai C, et al. Efficacy and safety of phentermine/topiramate in adults with overweight or obesity: a systematic review and meta-analysis. Obesity. 2021;29(6):985–94.PubMedCrossRef Lei X-G, Ruan J-Q, Lai C, et al. Efficacy and safety of phentermine/topiramate in adults with overweight or obesity: a systematic review and meta-analysis. Obesity. 2021;29(6):985–94.PubMedCrossRef
75.
go back to reference Chintam K, Chang AR. Strategies to treat obesity in patients with CKD. Am J Kidney Dis. 2021;77(3):427–39.PubMedCrossRef Chintam K, Chang AR. Strategies to treat obesity in patients with CKD. Am J Kidney Dis. 2021;77(3):427–39.PubMedCrossRef
76.
go back to reference Sherman MM, Ungureanu S, Rey JA. Naltrexone/bupropion ER (Contrave): newly approved treatment option for chronic weight management in obese adults. P t. 2016;41(3):164–72.PubMedPubMedCentral Sherman MM, Ungureanu S, Rey JA. Naltrexone/bupropion ER (Contrave): newly approved treatment option for chronic weight management in obese adults. P t. 2016;41(3):164–72.PubMedPubMedCentral
77.
go back to reference Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res. 2014;84:1–11.PubMedCrossRef Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res. 2014;84:1–11.PubMedCrossRef
78.
go back to reference Tak YJ, Lee SY. Anti-obesity drugs: long-term efficacy and safety: an updated review. World J Mens Health. 2021;39(2):208–21.PubMedCrossRef Tak YJ, Lee SY. Anti-obesity drugs: long-term efficacy and safety: an updated review. World J Mens Health. 2021;39(2):208–21.PubMedCrossRef
80.
go back to reference Khera R, Murad MH, Chandar AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016;315(22):2424–34.PubMedPubMedCentralCrossRef Khera R, Murad MH, Chandar AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016;315(22):2424–34.PubMedPubMedCentralCrossRef
81.
go back to reference Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19(1):110–20.PubMedCrossRef Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19(1):110–20.PubMedCrossRef
82.
go back to reference Christou GA, Kiortsis DN. The efficacy and safety of the naltrexone/bupropion combination for the treatment of obesity: an update. Hormones. 2015;14(3):370–5.PubMed Christou GA, Kiortsis DN. The efficacy and safety of the naltrexone/bupropion combination for the treatment of obesity: an update. Hormones. 2015;14(3):370–5.PubMed
83.
84.
go back to reference Halpern B, Halpern A. Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications. Expert Opin Drug Saf. 2015;14(2):305–15.PubMedCrossRef Halpern B, Halpern A. Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications. Expert Opin Drug Saf. 2015;14(2):305–15.PubMedCrossRef
85.
go back to reference Anderson JW. Orlistat for the management of overweight individuals and obesity: a review of potential for the 60-mg, over-the-counter dosage. Expert Opin Pharmacother. 2007;8(11):1733–42.PubMedCrossRef Anderson JW. Orlistat for the management of overweight individuals and obesity: a review of potential for the 60-mg, over-the-counter dosage. Expert Opin Pharmacother. 2007;8(11):1733–42.PubMedCrossRef
87.
go back to reference Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–61.PubMedCrossRef Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–61.PubMedCrossRef
89.
go back to reference Zhi J, Melia AT, Guerciolini R, et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther. 1994;56(1):82–5.PubMedCrossRef Zhi J, Melia AT, Guerciolini R, et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther. 1994;56(1):82–5.PubMedCrossRef
91.
go back to reference Bansal AB, Al Khalili Y. Orlistat. StatPearls. Treasure Island (FL): StatPearls Publishing. Copyright © 2023, StatPearls Publishing LLC.; 2023. Bansal AB, Al Khalili Y. Orlistat. StatPearls. Treasure Island (FL): StatPearls Publishing. Copyright © 2023, StatPearls Publishing LLC.; 2023.
92.
go back to reference Gentilella R, Bianchi C, Rossi A, et al. Exenatide: a review from pharmacology to clinical practice. Diabetes Obes Metab. 2009;11(6):544–56.PubMedCrossRef Gentilella R, Bianchi C, Rossi A, et al. Exenatide: a review from pharmacology to clinical practice. Diabetes Obes Metab. 2009;11(6):544–56.PubMedCrossRef
93.
go back to reference Apovian CM, Okemah J, O’Neil PM. Body weight considerations in the management of type 2 diabetes. Adv Ther. 2019;36(1):44–58.PubMedCrossRef Apovian CM, Okemah J, O’Neil PM. Body weight considerations in the management of type 2 diabetes. Adv Ther. 2019;36(1):44–58.PubMedCrossRef
94.
go back to reference Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–86.PubMedPubMedCentralCrossRef Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–86.PubMedPubMedCentralCrossRef
96.
go back to reference Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–32.PubMedCrossRef Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–32.PubMedCrossRef
97.
go back to reference Llewellyn DC, Logan Ellis H, Aylwin SJB, et al. The efficacy of GLP-1RAs for the management of postprandial hypoglycemia following bariatric surgery: a systematic review. Obesity (Silver Spring). 2023;31(1):20–30.PubMedCrossRef Llewellyn DC, Logan Ellis H, Aylwin SJB, et al. The efficacy of GLP-1RAs for the management of postprandial hypoglycemia following bariatric surgery: a systematic review. Obesity (Silver Spring). 2023;31(1):20–30.PubMedCrossRef
98.
go back to reference Iepsen EW, Torekov SS, Holst JJ. Liraglutide for type 2 diabetes and obesity: a 2015 update. Expert Rev Cardiovasc Ther. 2015;13(7):753–67.PubMedCrossRef Iepsen EW, Torekov SS, Holst JJ. Liraglutide for type 2 diabetes and obesity: a 2015 update. Expert Rev Cardiovasc Ther. 2015;13(7):753–67.PubMedCrossRef
99.
go back to reference Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med. 2022;70(1):5–13.PubMedCrossRef Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med. 2022;70(1):5–13.PubMedCrossRef
100.
go back to reference Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud. 2014;11(3–4):202–30.PubMedCrossRef Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud. 2014;11(3–4):202–30.PubMedCrossRef
101.
go back to reference Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46(2):100–9.PubMedCrossRef Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46(2):100–9.PubMedCrossRef
102.
go back to reference Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract. 2017;3(1):3–14.PubMedCrossRef Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract. 2017;3(1):3–14.PubMedCrossRef
103.
go back to reference Ryan PM, Hamilton JK. What do I need to know about liraglutide (Saxenda), the glucagon-like peptide 1 receptor agonist for weight management in children with obesity? Paediatr Child Health. 2022;27(4):201–2.PubMedPubMedCentralCrossRef Ryan PM, Hamilton JK. What do I need to know about liraglutide (Saxenda), the glucagon-like peptide 1 receptor agonist for weight management in children with obesity? Paediatr Child Health. 2022;27(4):201–2.PubMedPubMedCentralCrossRef
104.
go back to reference Brady SM, Kane MP, Busch RS. GLP-1 agonist use in a patient with an explainable cause of pancreatitis. AACE Clin Case Rep. 2016;2(2):e82–5.CrossRef Brady SM, Kane MP, Busch RS. GLP-1 agonist use in a patient with an explainable cause of pancreatitis. AACE Clin Case Rep. 2016;2(2):e82–5.CrossRef
106.
107.
go back to reference Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22.PubMedCrossRef Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22.PubMedCrossRef
108.
go back to reference Haase CL, Serratore Achenbach MG, Lucrezi G, et al. Use of liraglutide 3.0 mg for weight management in a real-world setting in Switzerland. Obes Facts. 2021;14(5):568–76.PubMedPubMedCentralCrossRef Haase CL, Serratore Achenbach MG, Lucrezi G, et al. Use of liraglutide 3.0 mg for weight management in a real-world setting in Switzerland. Obes Facts. 2021;14(5):568–76.PubMedPubMedCentralCrossRef
109.
go back to reference Lundgren JR, Janus C, Jensen SBK, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021;384(18):1719–30.PubMedCrossRef Lundgren JR, Janus C, Jensen SBK, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021;384(18):1719–30.PubMedCrossRef
110.
go back to reference Wadden TA, Tronieri JS, Sugimoto D, et al. Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial. Obesity. 2020;28(3):529–36.PubMedCrossRef Wadden TA, Tronieri JS, Sugimoto D, et al. Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial. Obesity. 2020;28(3):529–36.PubMedCrossRef
111.
go back to reference Garvey WT, Birkenfeld AL, Dicker D, et al. Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE insulin randomized controlled trial. Diabetes Care. 2020;43(5):1085–93.PubMedPubMedCentralCrossRef Garvey WT, Birkenfeld AL, Dicker D, et al. Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE insulin randomized controlled trial. Diabetes Care. 2020;43(5):1085–93.PubMedPubMedCentralCrossRef
112.
go back to reference Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes. 2013;37(11):1443–51.CrossRef Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes. 2013;37(11):1443–51.CrossRef
113.
go back to reference le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399–409.PubMedCrossRef le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399–409.PubMedCrossRef
114.
go back to reference Park JS, Kwon J, Choi HJ, et al. Clinical effectiveness of liraglutide on weight loss in South Koreans: first real-world retrospective data on Saxenda in Asia. Medicine (Baltimore). 2021;100(2): e23780.PubMedCrossRef Park JS, Kwon J, Choi HJ, et al. Clinical effectiveness of liraglutide on weight loss in South Koreans: first real-world retrospective data on Saxenda in Asia. Medicine (Baltimore). 2021;100(2): e23780.PubMedCrossRef
116.
go back to reference Lewis AL, McEntee N, Holland J, et al. Development and approval of rybelsus (oral semaglutide): ushering in a new era in peptide delivery. Drug Deliv Transl Res. 2022;12(1):1–6.PubMedCrossRef Lewis AL, McEntee N, Holland J, et al. Development and approval of rybelsus (oral semaglutide): ushering in a new era in peptide delivery. Drug Deliv Transl Res. 2022;12(1):1–6.PubMedCrossRef
118.
go back to reference Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.PubMedCrossRef Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.PubMedCrossRef
119.
go back to reference Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–64.PubMedPubMedCentralCrossRef Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–64.PubMedPubMedCentralCrossRef
120.
go back to reference Smith I, Hardy E, Mitchell S, et al. Semaglutide 2.4 mg for the management of overweight and obesity: systematic literature review and meta-analysis. Diabetes Metab Syndr Obes. 2022;15:3961–87.PubMedPubMedCentralCrossRef Smith I, Hardy E, Mitchell S, et al. Semaglutide 2.4 mg for the management of overweight and obesity: systematic literature review and meta-analysis. Diabetes Metab Syndr Obes. 2022;15:3961–87.PubMedPubMedCentralCrossRef
121.
go back to reference Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403–13.PubMedCrossRef Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403–13.PubMedCrossRef
122.
go back to reference Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971–84.PubMedCrossRef Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971–84.PubMedCrossRef
123.
go back to reference Farzam K, Patel P. Tirzepatide. StatPearls. Treasure Island (FL): StatPearls Publishing. Copyright © 2023, StatPearls Publishing LLC.; 2023. Farzam K, Patel P. Tirzepatide. StatPearls. Treasure Island (FL): StatPearls Publishing. Copyright © 2023, StatPearls Publishing LLC.; 2023.
124.
go back to reference Abbasi J. FDA green-lights tirzepatide, marketed as zepbound, for chronic weight management. JAMA. 2023;330(22):2143–4.PubMedCrossRef Abbasi J. FDA green-lights tirzepatide, marketed as zepbound, for chronic weight management. JAMA. 2023;330(22):2143–4.PubMedCrossRef
125.
go back to reference Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–16.PubMedCrossRef Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–16.PubMedCrossRef
127.
go back to reference Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402:613–26.PubMedCrossRef Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402:613–26.PubMedCrossRef
128.
go back to reference Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–15.PubMedCrossRef Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–15.PubMedCrossRef
129.
go back to reference Istfan NW, Anderson WA, Hess DT, et al. The mitigating effect of phentermine and topiramate on weight regain after Roux-en-Y gastric bypass surgery. Obesity (Silver Spring). 2020;28(6):1023–30.PubMedCrossRef Istfan NW, Anderson WA, Hess DT, et al. The mitigating effect of phentermine and topiramate on weight regain after Roux-en-Y gastric bypass surgery. Obesity (Silver Spring). 2020;28(6):1023–30.PubMedCrossRef
131.
go back to reference Nor Hanipah Z, Nasr EC, Bucak E, et al. Efficacy of adjuvant weight loss medication after bariatric surgery. Surg Obes Relat Dis. 2018;14(1):93–8.PubMedCrossRef Nor Hanipah Z, Nasr EC, Bucak E, et al. Efficacy of adjuvant weight loss medication after bariatric surgery. Surg Obes Relat Dis. 2018;14(1):93–8.PubMedCrossRef
133.
go back to reference Zoss I, Piec G, Horber FF. Impact of orlistat therapy on weight reduction in morbidly obese patients after implantation of the Swedish adjustable gastric band. Obes Surg. 2002;12(1):113–7.PubMedCrossRef Zoss I, Piec G, Horber FF. Impact of orlistat therapy on weight reduction in morbidly obese patients after implantation of the Swedish adjustable gastric band. Obes Surg. 2002;12(1):113–7.PubMedCrossRef
134.
go back to reference Miras AD, Pérez-Pevida B, Aldhwayan M, et al. Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(7):549–59.PubMedCrossRef Miras AD, Pérez-Pevida B, Aldhwayan M, et al. Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(7):549–59.PubMedCrossRef
135.
go back to reference Thakur U, Bhansali A, Gupta R, et al. Liraglutide augments weight loss after laparoscopic sleeve gastrectomy: a randomised, double-blind, Placebo-Control Study. Obes Surg. 2021;31(1):84–92.PubMedCrossRef Thakur U, Bhansali A, Gupta R, et al. Liraglutide augments weight loss after laparoscopic sleeve gastrectomy: a randomised, double-blind, Placebo-Control Study. Obes Surg. 2021;31(1):84–92.PubMedCrossRef
137.
go back to reference Wharton S, Kuk JL, Luszczynski M, et al. Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post-bariatric surgery. Clin Obes. 2019;9(4):e12323.PubMedPubMedCentralCrossRef Wharton S, Kuk JL, Luszczynski M, et al. Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post-bariatric surgery. Clin Obes. 2019;9(4):e12323.PubMedPubMedCentralCrossRef
138.
go back to reference Suliman M, Buckley A, Al Tikriti A, et al. Routine clinical use of liraglutide 3 mg for the treatment of obesity: outcomes in non-surgical and bariatric surgery patients. Diabetes Obes Metab. 2019;21(6):1498–501.PubMedCrossRef Suliman M, Buckley A, Al Tikriti A, et al. Routine clinical use of liraglutide 3 mg for the treatment of obesity: outcomes in non-surgical and bariatric surgery patients. Diabetes Obes Metab. 2019;21(6):1498–501.PubMedCrossRef
139.
go back to reference Muratori F, Vignati F, Di Sacco G, et al. Efficacy of liraglutide 3.0 mg treatment on weight loss in patients with weight regain after bariatric surgery. Eat Weight Disord. 2022;27(7):2775–81.PubMedPubMedCentralCrossRef Muratori F, Vignati F, Di Sacco G, et al. Efficacy of liraglutide 3.0 mg treatment on weight loss in patients with weight regain after bariatric surgery. Eat Weight Disord. 2022;27(7):2775–81.PubMedPubMedCentralCrossRef
140.
go back to reference Alameri M, Alnuaimi A, Fiad T. Outcomes of liraglutide as treatment for weight regain after bariatric surgery: a 2-year retrospective study. Endocr Abstr. 2019;65:416. Alameri M, Alnuaimi A, Fiad T. Outcomes of liraglutide as treatment for weight regain after bariatric surgery: a 2-year retrospective study. Endocr Abstr. 2019;65:416.
141.
go back to reference Pajecki D, Halpern A, Cercato C, et al. Short-term use of liraglutide in the management of patients with weight regain after bariatric surgery. Rev Col Bras Cir. 2013;40(3):191–5.PubMedCrossRef Pajecki D, Halpern A, Cercato C, et al. Short-term use of liraglutide in the management of patients with weight regain after bariatric surgery. Rev Col Bras Cir. 2013;40(3):191–5.PubMedCrossRef
142.
go back to reference Rye P, Modi R, Cawsey S, et al. Efficacy of high-dose liraglutide as an adjunct for weight loss in patients with prior bariatric surgery. Obes Surg. 2018;28(11):3553–8.PubMedCrossRef Rye P, Modi R, Cawsey S, et al. Efficacy of high-dose liraglutide as an adjunct for weight loss in patients with prior bariatric surgery. Obes Surg. 2018;28(11):3553–8.PubMedCrossRef
143.
go back to reference Colbourne JRM, Fisher OM, Mo S, et al. The role of adjuvant pharmacotherapy with liraglutide for patients with inadequate weight loss following bariatric surgery. Langenbecks Arch Surg. 2023;408(1):115.PubMedPubMedCentralCrossRef Colbourne JRM, Fisher OM, Mo S, et al. The role of adjuvant pharmacotherapy with liraglutide for patients with inadequate weight loss following bariatric surgery. Langenbecks Arch Surg. 2023;408(1):115.PubMedPubMedCentralCrossRef
144.
go back to reference Elhag W, El Ansari W. Effectiveness and safety of liraglutide in managing inadequate weight loss and weight regain after primary and revisional bariatric surgery: anthropometric and cardiometabolic outcomes. Obes Surg. 2022;32(4):1005–15.PubMedCrossRef Elhag W, El Ansari W. Effectiveness and safety of liraglutide in managing inadequate weight loss and weight regain after primary and revisional bariatric surgery: anthropometric and cardiometabolic outcomes. Obes Surg. 2022;32(4):1005–15.PubMedCrossRef
145.
go back to reference Lautenbach A, Wernecke M, Huber TB, et al. The potential of semaglutide once-weekly in patients without type 2 diabetes with weight regain or insufficient weight loss after bariatric surgery—a retrospective analysis. Obes Surg. 2022;32(10):3280–8.PubMedPubMedCentralCrossRef Lautenbach A, Wernecke M, Huber TB, et al. The potential of semaglutide once-weekly in patients without type 2 diabetes with weight regain or insufficient weight loss after bariatric surgery—a retrospective analysis. Obes Surg. 2022;32(10):3280–8.PubMedPubMedCentralCrossRef
146.
go back to reference Jensen AB, Renström F, Aczél S, et al. Efficacy of the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide for the treatment of weight regain after bariatric surgery: a retrospective observational study. Obes Surg. 2023;33(4):1017–25.PubMedPubMedCentralCrossRef Jensen AB, Renström F, Aczél S, et al. Efficacy of the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide for the treatment of weight regain after bariatric surgery: a retrospective observational study. Obes Surg. 2023;33(4):1017–25.PubMedPubMedCentralCrossRef
147.
go back to reference Murvelashvili N, Xie L, Schellinger JN, et al. Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence. Obesity. 2023;31(5):1280–9.PubMedCrossRef Murvelashvili N, Xie L, Schellinger JN, et al. Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence. Obesity. 2023;31(5):1280–9.PubMedCrossRef
148.
go back to reference Lafferty RA, Flatt PR, Irwin N. GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy. Expert Opin Pharmacother. 2023;24(5):587–97.PubMedCrossRef Lafferty RA, Flatt PR, Irwin N. GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy. Expert Opin Pharmacother. 2023;24(5):587–97.PubMedCrossRef
149.
go back to reference Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity. Endocr Pract. 2016;22:1–203.PubMedCrossRef Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity. Endocr Pract. 2016;22:1–203.PubMedCrossRef
151.
go back to reference McDuffie JR, Calis KA, Uwaifo GI, et al. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res. 2002;10(7):642–50.PubMedCrossRef McDuffie JR, Calis KA, Uwaifo GI, et al. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res. 2002;10(7):642–50.PubMedCrossRef
153.
154.
go back to reference Dharmaratnam VM, Lim E, Eng A, et al. Revisional surgery or pharmacotherapy for insufficient weight loss and weight regain after primary bariatric procedure: a descriptive study. Obes Surg. 2022;32(10):3298–304.PubMedCrossRef Dharmaratnam VM, Lim E, Eng A, et al. Revisional surgery or pharmacotherapy for insufficient weight loss and weight regain after primary bariatric procedure: a descriptive study. Obes Surg. 2022;32(10):3298–304.PubMedCrossRef
156.
go back to reference Galvani C, Gorodner M, Moser F, et al. Laparoscopic adjustable gastric band versus laparoscopic Roux-en-Y gastric bypass—ends justify the means? Surg Endosc. 2006;20:934–41.PubMedCrossRef Galvani C, Gorodner M, Moser F, et al. Laparoscopic adjustable gastric band versus laparoscopic Roux-en-Y gastric bypass—ends justify the means? Surg Endosc. 2006;20:934–41.PubMedCrossRef
157.
go back to reference Schwartz J, Suzo A, Wehr AM, et al. Pharmacotherapy in conjunction with a diet and exercise program for the treatment of weight recidivism or weight loss plateau post-bariatric surgery: a retrospective review. Obes Surg. 2016;26(2):452–8.PubMedCrossRef Schwartz J, Suzo A, Wehr AM, et al. Pharmacotherapy in conjunction with a diet and exercise program for the treatment of weight recidivism or weight loss plateau post-bariatric surgery: a retrospective review. Obes Surg. 2016;26(2):452–8.PubMedCrossRef
158.
go back to reference Badurdeen D, Hoff AC, Hedjoudje A, et al. Endoscopic sleeve gastroplasty plus liraglutide versus endoscopic sleeve gastroplasty alone for weight loss. Gastrointest Endosc. 2021;93(6):1316-24.e1.PubMedCrossRef Badurdeen D, Hoff AC, Hedjoudje A, et al. Endoscopic sleeve gastroplasty plus liraglutide versus endoscopic sleeve gastroplasty alone for weight loss. Gastrointest Endosc. 2021;93(6):1316-24.e1.PubMedCrossRef
Metadata
Title
Pharmacotherapy as an Augmentation to Bariatric Surgery for Obesity
Authors
Luděk Horváth
Miloš Mráz
Edward B. Jude
Martin Haluzík
Publication date
06-07-2024
Publisher
Springer International Publishing
Published in
Drugs
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-024-02029-0